Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

960 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.
Pfreundschuh M, Murawski N, Zeynalova S, Ziepert M, Loeffler M, Hänel M, Dierlamm J, Keller U, Dreyling M, Truemper L, Frickhofen N, Hünerlitürkoglu AN, Schmitz N, Pöschel V, Rixecker T, Berdel C, Rübe C, Held G, Zwick C. Pfreundschuh M, et al. Among authors: keller u. Br J Haematol. 2017 Nov;179(3):410-420. doi: 10.1111/bjh.14860. Epub 2017 Oct 8. Br J Haematol. 2017. PMID: 28990173 Free article. Clinical Trial.
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, Jaccard A, Reimer P, Wagner E, Wilhelm M, Sanhes L, Lamy T, de Leval L, Rosenwald A, Roussel M, Kroschinsky F, Lindemann W, Dreger P, Viardot A, Milpied N, Gisselbrecht C, Wulf G, Gyan E, Gaulard P, Bay JO, Glass B, Poeschel V, Damaj G, Sibon D, Delmer A, Bilger K, Banos A, Haenel M, Dreyling M, Metzner B, Keller U, Braulke F, Friedrichs B, Nickelsen M, Altmann B, Tournilhac O. Schmitz N, et al. Among authors: keller u. Blood. 2021 May 13;137(19):2646-2656. doi: 10.1182/blood.2020008825. Blood. 2021. PMID: 33512419 Free PMC article. Clinical Trial.
Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions.
Eigentler TK, Schlaak M, Hassel JC, Loquai C, Stoffels I, Gutzmer R, Pätzold S, Mohr P, Keller U, Starz H, Ulrich J, Tsianakas A, Kähler K, Hauschild A, Janssen E, Schuler-Thurner B, Weide B, Garbe C. Eigentler TK, et al. Among authors: keller u. J Immunother. 2014 Sep;37(7):374-81. doi: 10.1097/CJI.0000000000000046. J Immunother. 2014. PMID: 25075567
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, Falautano M, Nonis A, La Rosée P, Binder M, Fabbri A, Ilariucci F, Krampera M, Roth A, Hemmaway C, Johnson PW, Linton KM, Pukrop T, Gørløv JS, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Zanni M, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Thurner L, Cabras G, Pennese E, Ponzoni M, Deckert M, Politi LS, Finke J, Ferranti A, Cozens K, Burger E, Ielmini N, Cavalli F, Zucca E, Illerhaus G; IELSG32 study investigators. Ferreri AJM, et al. Among authors: keller u. Leukemia. 2022 Jul;36(7):1870-1878. doi: 10.1038/s41375-022-01582-5. Epub 2022 May 13. Leukemia. 2022. PMID: 35562406 Clinical Trial.
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
Liebers N, Duell J, Fitzgerald D, Kerkhoff A, Noerenberg D, Kaebisch E, Acker F, Fuhrmann S, Leng C, Welslau M, Chemnitz J, Middeke JM, Weber T, Holtick U, Trappe R, Pfannes R, Liersch R, Spoer C, Fuxius S, Gebauer N, Caillé L, Geer T, Koenecke C, Keller U, Claus R, Mougiakakos D, Mayer S, Huettmann A, Pott C, Trummer A, Wulf G, Brunnberg U, Bullinger L, Hess G, Mueller-Tidow C, Glass B, Lenz G, Dreger P, Dietrich S. Liebers N, et al. Among authors: keller u. Blood Adv. 2021 Jul 13;5(13):2707-2716. doi: 10.1182/bloodadvances.2020004155. Blood Adv. 2021. PMID: 34196677 Free PMC article.
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.
Stroh J, Seckinger A, Heider M, Rudelius M, Eichner R, Schick M, Slawska J, Emde-Rajaratnam M, Salwender H, Bertsch U, Goldschmidt H, Weisel K, Scheid C, Keller U, Hose D, Bassermann F. Stroh J, et al. Among authors: keller u. Blood Adv. 2022 Jan 25;6(2):515-520. doi: 10.1182/bloodadvances.2021005532. Blood Adv. 2022. PMID: 34768284 Free PMC article.
Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma.
Ng YLD, Ramberger E, Bohl SR, Dolnik A, Steinebach C, Conrad T, Müller S, Popp O, Kull M, Haji M, Gütschow M, Döhner H, Walther W, Keller U, Bullinger L, Mertins P, Krönke J. Ng YLD, et al. Among authors: keller u. Nat Commun. 2022 Feb 23;13(1):1009. doi: 10.1038/s41467-022-28515-1. Nat Commun. 2022. PMID: 35197447 Free PMC article.
960 results